MicrobiologybioRxivPreprint
Nafamostat Mesylate in lipid carrier for nasal SARS-CoV2 titer reduction in a hamster model
L. Cornelissen, E. Hoefsmit, D. Rao…·C. U. Blank
This study tests nasal application of nafamostat mesylate in liposomes to reduce SARS-CoV-2 viral load in hamsters, finding reduced nasal titer but no improvement in disease severity.
DOI 10.1101/2020.11.09.372375